Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.06.19
Views: 1357
Rating:

Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France

Dr Pierre Fenaux presents results at the 2019 European Hematology Association (EHA) Annual Meeting from IMerge study.

Use of single-agent imetelstat yielded an 8-week transfusion independence rate of 45%, with a median duration of 8.5 months and all patients with IPSS-R intermediate and poor cytogenetic risk responded.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation